- Home
- OMCL vs HROW Comparison
OMCL vs HROW Comparison
Compare OMCL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | HROW |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMCL | HROW |
|---|---|---|
| Price | $35.07 | $35.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $51.14 | ★ $71.14 |
| AVG Volume (30 Days) | 528.7K | ★ 936.9K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | $44.68 |
| Revenue Next Year | $5.22 | $40.71 |
| P/E Ratio | $876.50 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $20.85 |
| 52 Week High | $51.84 | $54.98 |
Technical Indicators
Market Signals| Indicator | OMCL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 32.18 |
| Support Level | $33.25 | $30.55 |
| Resistance Level | $37.51 | $40.64 |
| Average True Range (ATR) | 1.44 | 2.43 |
| MACD | -0.48 | -1.01 |
| Stochastic Oscillator | 14.03 | 8.09 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.